Brief: Tango Therapeutics Q3 Basic EPS USD -0.27
06/11/2024 12:05
Nov 06 (Reuters) - Tango Therapeutics Q3 net income USD -29.167 million vs. IBES estimate USD -37.8 million. * Q3 operating expenses USD 44.485 million * Q3 operating income USD -32.878 million vs. IBES estimate USD -41.5 million
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,